A causal role for IL-17A-dependent inflammation in driving psoriasis is highlighted by the success of monoclonal antibody-based therapies that bind IL-17A and block signaling through the IL-17A receptor [18, 21, 22]. This evidence concerns the gene IL17A and psoriasis.